Voyager Therapeutics (VYGR) EBITDA Margin (2015 - 2026)
Voyager Therapeutics (VYGR) reported EBITDA Margin of 1167.37% for Q1 2026, down 63141.0% on a YoY basis from N/an in Q1 2025, and down 499.6% sequentially from 194.69% in Q4 2025.
Voyager Therapeutics (VYGR) EBITDA Margin (2015 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 12 years of EBITDA Margin data on file, last reported at 1167.37% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 63141.0% year-over-year to 1167.37%; the trailing twelve-month figure through Mar 2026 stood at 348.79% (down 19681.0% YoY), and the FY2025 full-year result was 326.56%, down 22245.0% from the prior year.
- EBITDA Margin fell to 1167.37% in Q1 2026, from 194.69% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1584.71% in Q4 2022 to a low of 3244.68% in Q1 2022.
- A 5-year average of 528.85% and a median of 228.91% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin sank 285106 bps in 2022 and jumped 332634 bps in 2023, its largest moves.
- Tracing VYGR's EBITDA Margin over 5 years: stood at 1584.71% in 2022, then slumped by 96 bps to 60.0% in 2023, then sank by 1113 bps to 607.82% in 2024, then soared by 68 bps to 194.69% in 2025, then slumped by 500 bps to 1167.37% in 2026.
- Business Quant data shows VYGR's EBITDA Margin at 1167.37% in Q1 2026, 194.69% in Q4 2025, and 228.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Voyager Therapeutics | 184.74 Mn | 43.26 Mn | - | -1,167.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,167.37% |
| Dec 31, 2025 | -194.69% |
| Sep 30, 2025 | -228.91% |
| Jun 30, 2025 | -704.33% |
| Mar 31, 2025 | -535.96% |
| Dec 31, 2024 | -607.82% |
| Sep 30, 2024 | -55.95% |
| Jun 30, 2024 | -50.80% |
| Mar 31, 2024 | -82.99% |
| Dec 31, 2023 | 60.00% |
| Sep 30, 2023 | -639.51% |
| Jun 30, 2023 | -518.90% |
| Mar 31, 2023 | 81.66% |
| Dec 31, 2022 | 1,584.71% |
| Sep 30, 2022 | 35.15% |
| Jun 30, 2022 | -2,720.08% |
| Mar 31, 2022 | -3,244.68% |
| Dec 31, 2021 | 20.31% |
| Sep 30, 2021 | -1,696.76% |
| Jun 30, 2021 | -2,106.48% |